Trial Profile
Induction Chemotherapy Followed by radiotherapy combined with Nimotuzumab and Cisplatin/Docetaxel for Larynx Preservation: a Multicentor Randomized Phase II Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Apr 2016
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin; Docetaxel
- Indications Hypopharyngeal cancer; Laryngeal cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Apr 2016 New trial record